COSCIENS Biopharma Inc.
CSCIF
$1.97
-$0.07-3.43%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 394.31% | 67.57% | 68.39% | -89.94% | -160.89% |
| Total Depreciation and Amortization | 4.92% | -26.28% | -40.08% | -23.87% | -9.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -9,739.02% | -100.58% | -105.86% | 118.13% | 132.63% |
| Change in Net Operating Assets | -206.93% | -41.78% | 123.05% | -233.39% | 238.09% |
| Cash from Operations | -15.80% | 50.98% | 91.31% | -220.16% | 21.01% |
| Capital Expenditure | 99.67% | 85.11% | -- | 68.79% | -9.04% |
| Sale of Property, Plant, and Equipment | 125.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 214.29% | -- | -- | -- |
| Cash from Investing | 96.26% | 163.61% | -95.18% | -100.19% | -9.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 59.00% | 86.24% | 25.44% | 48.41% | -112.77% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | 59.00% | 92.57% | 54.79% | 15.08% | -112.77% |
| Foreign Exchange rate Adjustments | -133.33% | 176.14% | -166.67% | 364.18% | 144.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.64% | 66.24% | 89.64% | -118.21% | 16.93% |